Skip to main content
Nanomotor-Assisted Intravesical Chemotherapy for Bladder Tumor Reduction and Suppression of Early Tumor Regrowth.Fichna, K; Crespo-Cuadrado, M; Konuparamban, A; Di Carlo, V; Esporrin-Ubieto, D; Macias-Tarrio, I; Jutglar Soler, O; Chen, S; Gomez-Martinez, M; Bakenecker, AC; Vilaseca, A; Llop, J; Sanchez, SNano Lett., 2026,10.1021/acs.nanolett.5c05411
A brain-penetrant P2X7R antagonist mitigates Alzheimer's disease pathology.Turcu, AL; Oken, AC; Grinan-Ferre, C; Durner, A; Sierra-Marquez, J; Hinz-Kowalik, S; Nagel, J; Lee, SD; Tzortzini, E; Georgiou, K; Bhol, M; Baz, Z; Llop, J; Schneider, M; Barbaraci, C; Kim, GR; Barniol-Xicota, M; Val, C; Brea, J; Loza, MI; Perez, B; Naesens, L; Kolocouris, A; Kim, YC; Muller, CE; Nicke, A; Pallas, M; Mansoor, SE; Vazquez, SbioRxiv, 2026, , 102023
Longitudinal P2X7R and Myelin PET Reveal Distinct Neuroinflammatory and White Matter Signatures Compared with TSPO PET and DTI-MRI in the TgF344-AD rat modelMoreno, O; Fernández, I; Plaza-García, S; Padro, D; Baz, Z; Ramos-Cabrer, P; Martín, A; Llop, J. NeuroImage, 2026, , 121753
Increased levels of GFAP and purinergic P2X7 receptor in Alzheimer's disease brain are associated with Abeta, tau pathologies and synaptic loss.Maschio, CA; Moreno, O; Wang, J; Maheshwari, U; Keller, A; Konietzko, U; Razansky, D; Nordberg, A; Rominger, A; Hock, C; Llop, J; Nitsch, RM; Ni, RAlzheimer's Res. Ther., 2025,10.1186/s13195-025-01916-2
Longitudinal imaging evaluation of the inflammatory role of purinergic A2A receptors during subacute and chronic ischemic strokeGarbizu, M; Mocha-Munoz, N; Rubio-Lopez, E; Palacios, L; Aguado, L; Ardaya, M; Joya, A; Alduntzin, U; Plaza-Garcia, S; Padro, D; Gomez-Vallejo, V; Cossio, U; Higuchi, M; Ramos-Cabrer, P; Zugaza, JL; Llop, J; Martin, AJ. Cereb. Blood Flow Metab., 2025,10.1177/0271678X251370835
Unravelling the role of L- and D- alanine in prostate cancer: a Positron Emission Tomography study in a genetic mouse modelCastellnou, P; Gómez-Martínez, M; Gómez-Vallejo, V; Baz, Z; López-Gallego, F; Rondon-Lorefice, I; Zabala-Letona, A; Poot, AJ; Mendizabal, I; Carracedo, A; Rejc, L; Llop, J. Nucl Med Biol, 2025, 148-149, 109048
Chronic treatment with adenosine A1 receptor antagonist promotes neurogenesis and improves outcome after cerebral ischemia.Ardaya, M; Benito-Munoz, M; Rubio-Lopez, E; Garbizu, M; Aguado, L; Mocha-Munoz, N; Iglesias, L; Aldutzin, U; Matute, C; Soria, FN; Gomez-Vallejo, V; Garcia-Etxarri, A; Llop, J; Cavaliere, F; Martin, AJ. Cereb. Blood Flow Metab., 2025, , 271678X251345294
P2X7R antagonism suppresses long-lasting brain hyperexcitability following traumatic brain injury in miceAlves, M; de Diego-Garcia, L; Vegliante, G; Moreno, O; Gil, B; Ramos-Cabrer, P; Mitra, M; Martin, AF; Menéndez-Méndez, A; Wang, Y; Strogulski, NR; Sun, M; Melia, C; Conte, G; Plaza-García, S; Khalin, I; Teng, X; Plesnila, N; Klebl, B; Dinkel, K; Hamacher, M; Bhattacharya, A; Ceusters, M; Palmer, J; Loane, DJ; Llop, J; Henshall, DC; Engel, T. Theranostics, 2025, 15, 1399-1419
Short- and long-term changes in neurological, behavioural, and blood biomarkers following repeated mild traumatic brain injury in rats-potential biological sex-dependent effects.Moraga-Amaro, R; Moreno, O; Llop, J; Bankstahl, M; Bankstahl, JPFront. mol. neurosci, 2025, 18, 1488261
sfy39587stp18